Article Text
PDF
Abstract
The process of obtaining informed consent to participate in a clinical study presents many challenges for research conducted in a population of patients with schizophrenia. Morally valid, informed consent must include information sharing, decisional capacity, and capacity for voluntarism. This paper examines the unique features of schizophrenia that may threaten each of these elements of informed consent, and it proposes additional safeguards in the process of gaining informed consent from individuals with schizophrenia in order to maximise the decision-making potential of this patient population.
Statistics from Altmetric.com
Footnotes
↵i For more information on informed consent, see Faden RB, Beauchamp TL, King NMP, A history and theory of informed consent, Oxford University Press: New York, 1986.
Competing interests: None declared.
Read the full text or download the PDF:
Other content recommended for you
- Education versus screening: the use of capacity to consent tools in psychiatric genomics
- Adverse consequences of article 12 of the UN Convention on the Rights of Persons with Disabilities for persons with mental disabilities and an alternative way forward
- Vulnerability, therapeutic misconception and informed consent: is there a need for special treatment of pregnant women in fetus-regarding clinical trials?
- Emergency care research ethics in low-income and middle-income countries
- Can informed consent to research be adapted to risk?
- A pilot study to examine research subjects' perception of participating in research in the emergency department
- Vulnerability of pregnant women in clinical research
- Ethics and ego dissolution: the case of psilocybin
- Split views among parents regarding children’s right to decide about participation in research: a questionnaire survey
- Reconsenting paediatric research participants for use of identifying data